NCT04314024View on ClinicalTrials.gov

Relative Bioavailability (rBA) of Evobrutinib Intended Commercial and Clinical Tablets, and Effect of Food on Intended Commercial Tablets

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 25, 2020

Primary Completion Date

June 23, 2020

Study Completion Date

June 23, 2020

Conditions
Healthy
Interventions
DRUG

Evobrutinib

Participants will receive single oral dose of evobrutinib either after an overnight fast of at least 10 hours (Treatment A and Treatment B), or under fed conditions that is within 30 minutes after start of high-fat meal (Treatment C) in period 1, 2 and 3.

Trial Locations (1)

Unknown

Nuvisan GmbH, Neu-Ulm

All Listed Sponsors
lead

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT04314024 - Relative Bioavailability (rBA) of Evobrutinib Intended Commercial and Clinical Tablets, and Effect of Food on Intended Commercial Tablets | Biotech Hunter | Biotech Hunter